Standalone Implantation of Glaukos’ iStent inject® in Glaucoma Patients Results in Sustained IOP and Medication Reduction

Posted on

New results of an independent, international study by Glaukos Corporation in Advances in Therapy showed standalone implantation of the iStent inject®Trabecular Micro-Bypass System in eyes with substantial glaucoma disease burden achieved a 42% reduction in mean intraocular pressure (IOP) to 14.6 mmHg and an 82% reduction in mean medications to 0.55 at 3 years postoperative.

The consecutive case series examined 44 eyes and the long-term outcomes of the two-stent iStent inject system as a sole procedure in predominantly primary open-angle glaucoma patients. All procedures were performed at an academic ophthalmology center in Heidelberg, Germany.

3-year postoperative results included:

  • 97% of eyes achieved mean IOP ≤18 mmHg vs. 9.1% preoperatively (p<0.0001), and 70% of eyes achieved mean IOP ≤15 mmHg vs. 2.3% preoperatively (p<0.0001).
  • IOP decreased ≥20% vs. preoperative measurements in 88% of eyes.
  • 61% of eyes were medication free and all eyes maintained or decreased their three-year medication burden vs. preoperative levels.

“While iStent inject has been studied primarily in patients with mild-to-moderate open-angle glaucoma, [the] results add to an emerging body of evidence suggesting that our multiple-stent technology may also be a viable option for patients with more advanced disease, including those who have undergone prior surgeries,” said Thomas Burns, Glaukos president and chief executive officer.

You can read more here.

Related Articles
IOP outcomes after laser trabeculoplasty in eyes with prior Kahook Dual Blade goniotomy limited
Jul 28, 2021
Hydrus microstent reduces IOP, medication burden
Jul 26, 2021
IOP, gel microstents complications leading cause of reoperation after MIGS
Jul 23, 2021